Astellas (2023) Padcev (enfortumab vedotin-ejfv). Prescribing information (US).

Astellas (2024a) Padcev (enfortumab vedotin). Summary of product characteristics (European Medicines Agency).

Astellas (2024b) European Commission approves Astellas’ PADCEVTM (enfortumab vedotin) in combination with KEYTRUDA® (pembrolizumab) for first-line treatment of advanced urothelial cancer. https://www.astellas.com/en/news/29371. Accessed 3 September 2024.

Bilen MA, Robinson SB, Schroeder A, Peng J, Kim R, Liu FX, Bhanegaonkar A (2023) Clinical and economic outcomes in patients with metastatic urothelial carcinoma receiving first-line systemic treatment (the IMPACT UC I Study). Oncologist 28:790–798. https://doi.org/10.1093/oncolo/oyad174

Article  PubMed  PubMed Central  Google Scholar 

Bristol Myers Squibb (2024a) Opdivo (nivolumab). Prescribing information (US).

Bristol Myers Squibb (2024b) Opdivo (nivolumab). Summary of product characteristics (European Medicines Agency).

Brookmeyer R, Crowley J (1982) A confidence interval for the median survival time. Biometrics 38:29–41

Article  Google Scholar 

Cathomas R, Lorch A, Bruins HM, Compérat EM, Cowan NC, Efstathiou JA, Fietkau R, Gakis G, Hernández V, Espinós EL, Neuzillet Y, Ribal MJ, Rouanna M, Thalmann GN, van der Heijden AG, Vestkimäe E, Witjes JA, Milowsky MI, EAU Muscle-invasive, Metastatic Bladder Cancer Guidelines Panel (2022) The 2021 updated European Association of Urology guidelines on metastatic urothelial carcinoma. Eur Urol. 81:95–103. https://doi.org/10.1016/j.eururo.2021.09.026

Article  PubMed  Google Scholar 

Galsky MD, Arija JÁA, Bamias A, Davis ID, De Santis M, Kikuchi E, Garcia-Del-Muro X, De Giorgi U, Mencinger M, Izumi K, Panni S, Gumus M, Özgüroğlu M, Kalebasty AR, Park SH, Alekseev B, Schutz FA, Li JR, Ye D, Vogelzang NJ, Bernhard S, Tayama D, Mariathasan S, Mecke A, Thåström A, Grande E, IMvigor130 Study Group (2020) Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 395:1547–1557. https://doi.org/10.1016/S0140-6736(20)30230-0

Article  PubMed  CAS  Google Scholar 

German Guideline Program in Oncology. S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms S3-Leitlinie Harnblasenkarzinom—Version 2.01 (2019). https://www.leitlinienprogramm-onkologie.de/leitlinien/harnblasenkarzinom. Accessed 3 September 2024.

Geynisman DM, Broughton E, Hao Y, Zhang Y, Le T, Huo S (2022) Real-world treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in the United States. Urol Oncol 40:195.e191-195.e11. https://doi.org/10.1016/j.urolonc.2021.11.014

Article  CAS  Google Scholar 

Kearney M, Zhang L, Hubscher E, Musat M, Harricharan S, Wilke T (2023) Undertreatment in patients with advanced urothelial cancer: systematic literature review and meta-analysis. Future Oncol 20:1123–1137. https://doi.org/10.2217/fon-2023-0298

Article  PubMed  PubMed Central  Google Scholar 

Mahmoudpour SH, Knott C, Kearney M, Russo L, Verpillat P (2024) Factors associated with receipt of systemic anticancer treatment for locally advanced or metastatic urothelial carcinoma in England: a population-based study. Urol Oncol 42:451.e11-451.e18. https://doi.org/10.1016/j.urolonc.2024.07.010

Article  PubMed  CAS  Google Scholar 

Maráz A, Nagy B, Macher T, Jeskó J, Tischler E, Csongvai C, Kearney M (2023) Nationwide study of real-world treatment patterns and clinical outcomes in patients with metastatic urothelial carcinoma in Hungary. Adv Ther 40:5475–5488. https://doi.org/10.1007/s12325-023-02694-9

Article  PubMed  PubMed Central  CAS  Google Scholar 

Merck (2021) European Commission approves BAVENCIO® (avelumab) for first-line maintenance treatment of locally advanced or metastatic urothelial carcinoma. https://www.merckgroup.com/en/news/bavencio-1l-uc-eu-approval-25-01-2021.html. Accessed 3 September 2024.

Milloy N, Kirker M, Unsworth M, Montgomery R, Kluth C, Kearney M, Chang J (2024) Real-world analysis of treatment patterns and platinum-based treatment eligibility of patients with metastatic urothelial cancer in 5 European countries. Clin Genitourin Cancer 22:e136-147.e131. https://doi.org/10.1016/j.clgc.2023.09.010

Article  PubMed  Google Scholar 

Morgans AK, Galsky MD, Wright P, Hepp Z, Chang N, Willmon CL, Sesterhenn S, Liu Y, Sonpavde GP (2023) Real-world treatment patterns and clinical outcomes with first-line therapy in patients with locally advanced/metastatic urothelial carcinoma by cisplatin-eligibility. Urol Oncol 41:357.e11-357.e21. https://doi.org/10.1016/j.urolonc.2023.03.012

Article  PubMed  CAS  Google Scholar 

NCCN Clinical Practice Guidelines in Oncology: Bladder cancer. V4.2024. https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf. Accessed 3 September 2024.

Niegisch G, Gerullis H, Lin SW, Pavlova J, Gondos A, Rudolph A, Haas G, Hennies N, Kramer MW (2018) A real-world data study to evaluate treatment patterns, clinical characteristics and survival outcomes for first- and second-line treatment in locally advanced and metastatic urothelial cancer patients in Germany. J Cancer 9:1337–1348. https://doi.org/10.7150/jca.23162

Article  PubMed  PubMed Central  CAS  Google Scholar 

Niegisch G, Grimm MO, Hardtstock F, Krieger J, Starry A, Osowski U, Guenther S, Deiters B, Maywald U, Wilke T, Kearney M (2024a) Treatment patterns and clinical outcomes in metastatic urothelial carcinoma: a German retrospective real-world analysis. Future Oncol 20:1351–1366. https://doi.org/10.2217/fon-2023-1065

Article  PubMed  PubMed Central  Google Scholar 

Niegisch G, Grimm MO, Hardtstock F, Krieger J, Starry A, Osowski U, Guenther S, Deiters B, Maywald U, Wilke T, Kearney M (2024b) Healthcare resource utilization and associated costs in patients with metastatic urothelial carcinoma: a real-world analysis using German claims data. J Med Econ 27:531–542. https://doi.org/10.1080/13696998.2024.2331893

Article  PubMed  Google Scholar 

Niegisch G, Kearney M, Krieger J, Osowski U, Deiters B, Maywald U, Wilke T, Grimm MO (2024c). Insights into second-line systemic treatment selection in patients with metastatic urothelial carcinoma: results of a retrospective observational study in Germany. Ann Oncol. 35(suppl 2):Abstract 1995P.

Powles T, Csőszi T, Özgüroğlu M, Matsubara N, Géczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Morales Barrera R, Fléchon A, Gunduz S, Loriot Y, Rodriguez-Vida A, Mamtani R, Yu EY, Nam K, Imai K, Homet Moreno B, Alva A, KEYNOTE-361 Investigators (2021) Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol 22:931–945. https://doi.org/10.1016/S1470-2045(21)00152-2

Article  PubMed  CAS  Google Scholar 

Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, Necchi A, Valderrama BP, Ravaud A, Shariat SF, Szabados B, van der Heijden MS, Gillessen S, ESMO Study Guidelines Committee (2022) Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 33:244–258. https://doi.org/10.1016/j.annonc.2021.11.012

Article  PubMed  CAS  Google Scholar 

Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, Necchi A, Valderrama BP, Ravaud A, Shariat SF, Szabados B, van der Heijden MS, Gillessen S, ESMO Study Guidelines Committee (2024a) ESMO clinical practice guideline interim update on first-line therapy in advanced urothelial carcinoma. Ann Oncol 35:485–490. https://doi.org/10.1016/j.annonc.2024.03.001

Article  PubMed  CAS  Google Scholar 

Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C, Park SH, Shin SJ, Castellano D, Fornarini G, Li JR, Gümüş M, Mar N, Loriot Y, Fléchon A, Duran I, Drakaki A, Narayanan S, Yu X, Gorla S, Homet Moreno B, van der Heijden MS (2024b) Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med 390:875–888. https://doi.org/10.1056/NEJMoa2312117

Article  PubMed  CAS  Google Scholar 

Puente J, Pinto A, Mendez Vidal MJ, Garcia del Muro X, Maroto-Rey P, Vazquez-Estevez S, Luque R, Anido U, Strunz-McKendry T, Upadhyay A, Montes J, Ortiz Nuñez A, González Portela J, Castellano D (2023) Real-world treatment patterns, survival outcomes, and health care resource utilization (HCRU) for locally advanced or metastatic urothelial carcinoma (la/mUC) in Spain. J Clin Oncol 41(Suppl 6):Abstract 463. https://doi.org/10.1200/JCO.2023.41.6_suppl.463

Article  Google Scholar 

Robert Koch Institut (2024) Cancer in Germany 2019/2020. https://www.krebsdaten.de/Krebs/EN/Content/Publications/Cancer_in_Germany/cancer_in_germany.html. Accessed 21 January 2025.

Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A (2020) Epidemiology of bladder cancer. Med Sci (Basel) 8:15. https://doi.org/10.3390/medsci8010015

Article  PubMed  CAS  Google Scholar 

Schlack K, Kubin T, Ruhnke M, Schulte C, Machtens S, Eisen A, Osowski U, Guenther S, Kearney M, Lipp R, Schmitz S (2023) Split-dose cisplatin plus gemcitabine use and associated clinical outcomes in the first-line (1L) treatment of locally advanced or metastatic urothelial cancer (la/mUC): results of a retrospective observational study in Germany (CONVINCE). Ann Oncol 34(Suppl 2):2388. https://doi.org/10.1016/annonc/annonc1310

Article  Google Scholar 

Suissa S (2007) Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf 16:241–249. https://doi.org/10.1002/pds.1357

Article  PubMed  Google Scholar 

Tricotel A, Casarotto E, Minacori R, Strunz-McKendry T, Karzazi K, Leyland K, Vuillet M, Thomas MC, Joly F, Rouprêt M, Culine S (2024) Treatment patterns, healthcare resource utilization, and costs of patients with locally advanced and metastatic urothelial cancer in France: a non-interventional database study. Value Health. 27(suppl 2):831

Google Scholar 

US Department of Health and Human Services (2017) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf. Accessed 3 September 2024.

US Food and Drug Administration (2023) FDA approves enfortumab vedotin-ejfv with pembrolizumab for locally advanced or metastatic urothelial cancer. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-enfortumab-vedotin-ejfv-pembrolizumab-locally-advanced-or-metastatic-urothelial-cancer. Accessed 3 September 2024.

van der Heijden MS, Sonpavde G, Powles T, Necchi A, Burotto M, Schenker M, Sade JP, Bamias A, Beuzeboc P, Bedke J, Oldenburg J, Chatta G, Ürün Y, Ye D, He Z, Valderrama BP, Ku JH, Tomita Y, Filian J, Wang L, Purcea D, Patel MY, Nasroulah F, Galsky MD (2023) Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma. N Engl J Med 389:1778–1789. https://doi.org/10.1056/NEJMoa2309863

Article  PubMed  Google Scholar